| Description |
The 4th Annual Biomarkers Congress, presented by Oxford Global Conferences, will provide a first class educational and networking opportunity for over 200 attendees from leading pharmaceutical, biotechnology, diagnostics and clinical research companies as well as academic institutions in the UK, Europe and the US. It will take place on the 26 and 27 February 2009, at the Midland Hotel, Manchester UK.
Over two days the comprehensive scientific conference programme will feature keynote addresses, case study presentations, panel and roundtable discussions from over 40 speakers giving insight on how to effectively manage and streamline your Development process. Topics being covered at the Summit include:-
Biomarker Discovery and Validation: Focus upon methods to accelerate discovery and validation in order to maximise efficiency and reduce costs as well as insight on the regulatory influences of biomarkers and approaches and strategies of the Critical Path Institute
Data Integration, Bioinformatics, Modelling and Molecular Diagnostics: Developing successful integration of these tools within the preclinical and development process
Biomarkers in Clinical Development: Implementing biomarkers as the main drivers of personalised medicine and utilising biomarkers as valuable decision making tools in clinical drug development
Biomarker Discovery & Validation: Therapeutic Case Studies: Ensuring more predictive biomarkers by accessing discovery and validation
techniques in various therapeutic areas
Imaging in Discovery & Clinical Development & Enabling Technologies to Maximise Biomarker Identification: Examining various imaging techniques to identify biomarkers and critical analysis of other enabling technologies
Confirmed speakers at the event include:-
• Chairman, EMEA Scientific Advice Working Party, Federal Agency for Medicinal and Health Products, Belgium
• Senior Vice President Research and Development, AstraZeneca
• Head Molecular Profiling Technologies, Translational Medicine Research Centre Singapore, Schering-Plough
• Director, Global Discovery Medicine, Respiratory & Inflammation Therapy Area, AstraZeneca
• Director, Global Exploratory Stats, Global Stats & Data Management, Abbott
• Director Stevenage Core Technologies Group, Discovery Technology Group, GlaxoSmithKline
• Director Pharmacogenetics, Schering Plough
• R&D Director, Horizon Discovery
• Associate Director Molecular Biomarkers, UCB Group
• Associate Director, Molecular Sciences, Amgen
• Head of Molecular Toxicology, Merck Serono Research
• Clinical Project Leader, Bayer Healthcare
• Senior Principal Scientist, Biomarker Lead, Pharmacokinetics, Dynamics, and Metabolism, Pfizer
• Biomarker - Experimental Medicine Leader, F. Hoffmann-La Roche
• Head of PK/PD Assay Development Group, Novartis Biologics
• Clinical Science & Technology, Neurosciences CEDD, GlaxoSmithKline
• Translations Medicine Scientist, International Clinical Research, Lundbeck
• Founder, Chairman & CSO, Bio-Modeling Systems
• Professor, Scientific Director Head of Translational Neurobiology, NeuroSearch
• Head of Cancer Proteomics Laboratory, Institute for Women's Health, UCL
• Associate Professor, University College Dublin
• Associate Professor of Biology and Chemistry, Ryerson University
• Director Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology College of Science and Technology, Temple University
• Team Leader - Cancer Informatics Reader of Cancer Informatics ICR, Breakthrough Breast Cancer Research Centre The Institute of Cancer Research
• Cancer Biomarker Reference Laboratory, National Institute of Standards & Technology
• Senior Research Associate, Case Western Reserve University
• Assistant Professor, Dept. of Immunotechnology, Lund University
• Professor of Internal Medicine / Medical Oncology Innsbruck University
Early bird discounts are available by quoting “BIOMDEL01”. For information on sponsorship please email sponsorship@oxfordglobal.co.uk or call +44(0) 1865 811196. www.biomarkers-congress.com.
|
|
